Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.

Item
http://www.wikidata.org/entity/Q52041523
Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat.Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system.Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine.Cytochrome P450 polymorphisms and response to antipsychotic therapy.Addressing phenoconversion: the Achilles' heel of personalized medicine.Clinically significant psychotropic drug-drug interactions in the primary care setting.CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine.CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards.Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics.Movement disturbances associated with the use of selective serotonin-reuptake inhibitors.A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia
P2860

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.

Item
http://www.wikidata.org/entity/Q52041523
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Paroxetine potentiates the cen ...... me P4502D6 inhibition in vivo.
@en
Paroxetine potentiates the cen ...... me P4502D6 inhibition in vivo.
@nl
type
label
Paroxetine potentiates the cen ...... me P4502D6 inhibition in vivo.
@en
Paroxetine potentiates the cen ...... me P4502D6 inhibition in vivo.
@nl
prefLabel
Paroxetine potentiates the cen ...... me P4502D6 inhibition in vivo.
@en
Paroxetine potentiates the cen ...... me P4502D6 inhibition in vivo.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Paroxetine potentiates the cen ...... me P4502D6 inhibition in vivo.
@en
P2093
P2860
P304
P31
P356
10.1016/S0009-9236(97)90037-0
P407
P433
P478
P577
P698